| Literature DB >> 32309102 |
Allison C Hu1, Seung Ah Lee1, Emily G Clark1, Maki Yamamoto2, James G Jakowatz2, Gregory R D Evans1.
Abstract
BACKGROUND: The role of surgical reconstruction following melanoma extirpation is well recognized. Although technical considerations depend on patient anatomy and surgeon preference, the optimal timing of reconstruction remains unclear. This study aims to evaluate clinical and oncologic outcomes in melanoma extirpation followed by immediate reconstruction.Entities:
Year: 2020 PMID: 32309102 PMCID: PMC7159960 DOI: 10.1097/GOX.0000000000002661
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Fig. 1.Melanoma lesion in the left upper cheek.
Fig. 5.Patient shown 3 months after excision with negative margins.
Patient Demographics
| Characteristic | Value (%), n = 197 |
|---|---|
| Mean age, y (range) | 67.3 (16–95) |
| Sex | |
| Female | 58 (29.4%) |
| Male | 139 (70.6%) |
| Skin cancer history | |
| None | 127 (64.5%) |
| One type | 44 (22.3%) |
| Two types | 21 (10.7%) |
| Three types | 5 (2.5%) |
| Medical history | |
| Melanoma | 46 (65.7%) |
| Squamous cell carcinoma | 27 (38.6%) |
| Basal cell carcinoma | 27 (38.6%) |
| Not otherwise specified | 1 (1.4%) |
| Skin cancer history | |
| Melanoma | 31 (44.3%) |
| Melanoma + SCC | 7 (10.0%) |
| Melanoma + BCC | 3 (4.3%) |
| Melanoma + SCC + BCC | 5 (7.1%) |
| SCC | 4 (5.7%) |
| SCC + BCC | 11 (15.7%) |
| BCC | 8 (11.4%) |
| Not otherwise specified | 1 (1.4%) |
| Mean length of follow-up, y (range) | 2.3 (0–5.9) |
Tumor Characteristics
| Characteristic | Value (%), n = 202 |
|---|---|
| Melanoma type | |
| In situ | 64 (31.7) |
| Invasive | 138 (68.3) |
| Mean Breslow thickness, mm (SD) | 1.5 (2.2) |
| AJCC tumor classification | |
| Tis | 64 (31.7) |
| T1a | 58 (28.7) |
| T1b | 20 (9.9) |
| T2a | 24 (11.9) |
| T2b | 7 (3.5) |
| T3a | 10 (5.0) |
| T3b | 3 (1.5) |
| T4a | 9 (4.5) |
| T4b | 3 (1.5) |
| N/A | 4 (2.0) |
| Anatomic location | |
| Cheek | 69 (34.2) |
| Scalp | 63 (31.2) |
| Ear | 19 (9.4) |
| Nose | 16 (7.9) |
| Temple | 16 (7.9) |
| Forehead | 14 (6.9) |
| Neck | 2 (1.0) |
| Lip | 2 (1.0) |
| Chin | 1 (0.5) |
| Laterality | |
| Right | 74 (36.6) |
| Left | 85 (42.1) |
| N/A | 43 (21.3) |
| Number upstaged | 21 (10.7) |
| Number positive margins | 2 (0.9) |
| Number recurrence | 5 (2.5) |
| Mean time to recurrence, m (SD) | 12.4 (6.2) |
AJCC, American Joint Committee on Cancer; N/A, not available; Tis, tumor in situ.
Operative Variables
| Characteristic | Value (%) |
|---|---|
| Mean time in operating room, min (range) | |
| Total OR time | 130.7 (46–320) |
| Surgery time | 81.9 (21–233) |
| Mean excision margins, cm | |
| Tis | 0.8 |
| T1 | 1.1 |
| T2 | 1.4 |
| T3 | 1.9 |
| T4 | 1.9 |
| Sentinel lymph node biopsy | |
| Yes | 69 (34.1%) |
| No | 133 (65.8%) |
| Sentinel lymph node biopsy for each AJCC T category | |
| Tis | 0 (0%) |
| T1a | 8 (13.8%) |
| T1b | 14 (70.0%) |
| T2a | 18 (75.0%) |
| T2b | 4 (57.1%) |
| T3a | 8 (80.0%) |
| T3b | 3 (100%) |
| T4a | 7 (77.8%) |
| T4b | 3 (100.0%) |
| N/A | 4 (100%) |
| Mean defect length, cm (range) | |
| Minimum length | 3.6 (1–11) |
| Maximum length | 4.5 (1–15) |
| Reconstruction modality | |
| Primary closure | 23 (11.4%) |
| Adjacent tissue transfer | 116 (57.4%) |
| FTSG | 24 (11.9%) |
| STSG | 17 (8.4%) |
| More than 1 technique | 22 (10.9%) |
| Types of adjacent tissue transfer | |
| Advancement flap | 57 (45.2%) |
| Transposition flap | 33 (26.2%) |
| Rotational flap | 30 (23.8%) |
| Local flap | 3 (2.4%) |
| Face-lift flap | 3 (2.4%) |
AJCC, American Joint Committee on Cancer; FTSG, full-thickness skin graft; N/A, not available; OR, operating room; STSG, split-thickness skin graft; Tis, tumor in situ.
Recurrence Cohort
| Age | Sex | Skin Cancer History | Melanoma Type | Location | Tumor Thickness (mm) | AJCC Tumor Classification | Margins (cm) | Defect Size (cm) | SLNB | Initial Reconstruction | Time to Recurrence (m) | Margins at Reoperation (cm) | Reconstruction at Reoperation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77 | M | Melanoma, SCC | NOS | Scalp | 1.5 | T2a | 2 | 6 × 6 | Yes; negative | FTSG | 22.5 | 1.5 | FTSG |
| 86 | M | None | Nodular | Nose | 1.3 | T2a | 1.5 | 2.5 × 4 | No | Advancement flap, FTSG | 8.5 | N/A | Advancement flap |
| 66 | M | Melanoma, SCC, BCC | NOS | Cheek | 0.3 | T1a | 1 | 3.5 × 3.5 | No | Advancement flap | 6.6 | 0.8 | Z-plasty |
| 87 | M | Melanoma | NOS | Cheek | 0.9 | T1b | 1 | 4 × 4 | Yes; negative | Advancement flap | 10.8 | 1 | Advancement flap |
| 58 | M | None | NOS | Scalp | 3.8 | T3a | 2 | 8.5 × 9 | Yes; negative | STSG | 13.6 | N/A | FTSG |
AJCC, American Joint Committee on Cancer; FTSG, full-thickness skin graft; M, male; N/A, not available; NOS, not otherwise specified; SLNB, sentinel lymph node biopsy; STSG, split-thickness skin graft.
Positive Margins Cohort
| Age | Sex | Skin Cancer History | Melanoma Type | Location | Tumor Thickness (mm) | AJCC Tumor Classification | Margins (cm) | Defect Size (cm) | SLNB | Initial Reconstruction | Margins at Reoperation (cm) | Reconstruction at Reoperation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | F | Melanoma | Nodular | Nose | FNA | FNA | 1 | 3.5 × 3.5 | Yes; negative | Cheek rotational flap, nasalis muscle flap, intraoral advancement flap, Integra | N/A | Cheek rotational flap, RFFF, FTSG, STSG |
| 68 | F | SCC and BCC | NOS | Scalp | 0.5 | T1a | 1 | 1.8 × 3 | No | Local tissue rearrangement | 0.5 | Primary closure |
AJCC, American Joint Committee on Cancer; F, female; FNA, fine-needle aspiration; FTSG, full-thickness skin graft; N/A, not available; NOS, not otherwise specified; RFFF, radial free forearm flap; SLNB, sentinel lymph node biopsy; STSG, split-thickness skin graft.
Published Rates of Positive Margins after WLE of Head and Neck Malignant Melanoma
| Study | Rate of Positive Margins (Number/Total) | Location | Reconstruction Modality | Average Follow-Up Time (mo) |
|---|---|---|---|---|
| Demer et al[ | 6.2% (6/97) | Head and neck, NOS | N/A | 20 |
| Koolen et al[ | 18.8% (39/207) | Head and neck, NOS | N/A | 48.2 |
| Miller et al[ | 12.1% (25/207) | Head and neck, NOS | N/A | N/A |
| Karanetz et al[ | 1.7% (9/534) | Cheek (6) | N/A | 14.4 |
| Mangold et al[ | 14.1% (19/135) | Head and neck, NOS | N/A | 56.4* |
| Parrett et al[ | 5.3% (4/76) | Cheek (2) | Rhomboid flap (2) | 24* |
| Christophel et al[ | 11.7% (48/412) | Cheek (15) | N/A | N/A |
| Sullivan et al[ | 1.4% (1/72) | Scalp | Adjacent tissue transfer | 62.4 |
| Sullivan et al[ | 6.0% (7/117) | Cheek (5) | Adjacent tissue transfer (4) | N/A |
| Berdahl et al[ | 5.0% (2/40) | Upper face, NOS | N/A | 37.6 |
| Glat et al[ | 2.5% (1/40) | Periorbital | Full-thickness skin graft | 68.4 |
*Median reported.
N/A, not available; NOS, not otherwise specified.
Published Rates of Recurrence after Obtaining Negative Margins following WLE of Head and Neck Malignant Melanoma and Immediate Reconstruction
| Study | Rate of Recurrence (Number/Total) | Reconstruction Modality | Average Follow-Up Time (mo) |
|---|---|---|---|
| Koolen et al[ | 49.0% (70/143) | Skin graft (35) | 47.8 |
| Parrett et al[ | 2.6% (2/76) | N/A | 24* |
| Sullivan et al[ | 1.4% (1/72) | Full-thickness skin graft (1) | 62.4 |
| Buck et al[ | 5.9% (3/51) | N/A | 26.9 |
| Sekido et al[ | 0% (0/34) | 0 | 36 |
| Glat et al[ | 0% (0/40) | 0 | 68.4 |
| Lent et al[ | 0% (0/36) | 0 | 37.5 |
*Median reported.
N/A, not available.